Thermo Fisher Scientific Inc. (TMO)

Over the past six months (November 2025 - May 2026), Thermo Fisher Scientific's stock (TMO) has experienced several notable events and trends. The stock was trading at $579.42 at the beginning of 2026 and has since decreased by 19.8% to $464.6370 as of early May 2026. The company reported strong fourth-quarter 2025 results, with revenue and earnings exceeding expectations. Thermo Fisher Scientific increased its quarterly dividend from $0.43 to $0.47 per share, which was paid on April 15, 2026. The company reported Q1 2026 results that beat top- and bottom-line estimates, with adjusted EPS of $5.44 and revenue of $11.01 billion. Thermo Fisher Scientific announced an agreement to sell its microbiology business to Astorg for approximately $1.075 billion. The stock performance has been influenced by broader macroeconomic and life sciences industry headwinds, including cautious spending from biotech customers and the normalization of post-pandemic activity. The company's increased debt load following the Clario acquisition has also been cited as a factor impacting the stock. Significant insider selling has also been noted as a factor affecting the stock.

Demand seasonality for Thermo Fisher Scientific's products and services is a factor in its financial performance. The company's sales and cash flow are seasonally higher in the fourth quarter as customers often rush to spend their research budgets by year-end. While seasonality in stock price performance by calendar month is analyzed, specific detailed monthly trends are typically available through specialized financial analysis tools that require a login for access.

Thermo Fisher Scientific Inc. is a global leader in serving science, providing a comprehensive range of products and services to advance life science research, solve complex analytical challenges, improve patient health, and increase laboratory productivity. The company operates within the life science and clinical research sector, encompassing industries such as laboratory equipment, biotechnology, chemicals, pharmaceutical, and healthcare. Its core business involves supplying analytical instruments, reagents and consumables, software, and services to a diverse customer base. Thermo Fisher Scientific operates through four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

Thermo Fisher Scientific maintains a significant global presence, with operations and sales spanning North America, Europe, Asia-Pacific, and other international markets. The United States is its largest market, contributing approximately 48% to 53% of its total revenues. China has emerged as the company's second-largest market.

Thermo Fisher Scientific maintains a strong brand reputation, recognized for its contributions to scientific research and healthcare. The company has been listed among "Fortune's America's Most Innovative Companies" (#18) and "America's Best Employers For Company Culture" (#507) in 2026. It is also recognized as a "Net Zero Leader" for its commitment to environmental responsibility, with a 29% reduction in Scope 1+2 emissions from its 2018 baseline. In the past year, a notable positive event for its reputation was a collaboration with OpenAI to deploy GPT-Rosalind, a new AI model aimed at accelerating drug discovery workflows. No specific negative events significantly impacting its brand reputation in the past year were found in the provided information.

Thermo Fisher Scientific's ownership is predominantly institutional, with institutions holding approximately 91% of outstanding shares as of late 2025. Major institutional owners include The Vanguard Group, BlackRock Institutional Trust, State Street Investment Management, Capital World Investors, Geode Capital Management, Fidelity Management & Research, and T. Rowe Price Associates. Individual and executive ownership remains below 1%.